Abstract
Organophosphate nerve agents are still considered as potential threats in both military and terrorism situations. They are potent irreversible inhibitors of acetylcholinesterase in central and also in peripheral compartment. Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for human use or is in course of clinical trials for the treatment of Alzheimers disease. This compound has also been successfully tested for pretreatment of organophosphate poisoning. In this study Hup A was tested as a prophylaxis against two V-nerve agents (VX and Russian VX). According to the obtained results, Hup A was able to partially protect AChE in the blood, diaphragm and brain against inhibition caused by Russian VX and VX.
Keywords: Huperzine A, VX, Russian VX, Brain, Nerve agent, Acetylcholinesterase, Pretreatment
Letters in Drug Design & Discovery
Title: Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX
Volume: 6 Issue: 8
Author(s): Jana Zdarova Karasova, Jiri Bajgar, Ladislav Novotny and Kamil Kuca
Affiliation:
Keywords: Huperzine A, VX, Russian VX, Brain, Nerve agent, Acetylcholinesterase, Pretreatment
Abstract: Organophosphate nerve agents are still considered as potential threats in both military and terrorism situations. They are potent irreversible inhibitors of acetylcholinesterase in central and also in peripheral compartment. Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for human use or is in course of clinical trials for the treatment of Alzheimers disease. This compound has also been successfully tested for pretreatment of organophosphate poisoning. In this study Hup A was tested as a prophylaxis against two V-nerve agents (VX and Russian VX). According to the obtained results, Hup A was able to partially protect AChE in the blood, diaphragm and brain against inhibition caused by Russian VX and VX.
Export Options
About this article
Cite this article as:
Karasova Zdarova Jana, Bajgar Jiri, Novotny Ladislav and Kuca Kamil, Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX, Letters in Drug Design & Discovery 2009; 6 (8) . https://dx.doi.org/10.2174/157018009789353419
DOI https://dx.doi.org/10.2174/157018009789353419 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30
Current Alzheimer Research Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry The Impact of Dementia Development Concurrent with Parkinson's Disease: A New Perspective
CNS & Neurological Disorders - Drug Targets G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design The Therapeutic Potential of Quercetin in Parkinson’s Disease: Insights into its Molecular and Cellular Regulation
Current Drug Targets The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Modeling Cardiovascular Development: New Approaches are Making In Vitro En Vogue
Current Cardiology Reviews Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy Regional Cerebral Blood Flow and Cerebrovascular Reactivity in Alzheimer’s Disease and Vascular Dementia Assessed by Arterial Spinlabeling Magnetic Resonance Imaging
Current Neurovascular Research Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System
Current Neuropharmacology Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Pharmacological Management of Huntingtons Disease: An Evidence- Based Review
Current Pharmaceutical Design Thalamocortical Oscillations: Local Control of EEG Slow Waves
Current Topics in Medicinal Chemistry Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models
Current Neuropharmacology Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry TRP Channels and Pain
Current Pharmaceutical Design Increased Neuronal Injury in Transgenic Mice with Neuronal Overexpression of Human Cyclooxygenase-2 is reversed by Hypothermia and Rofecoxib Treatment
Current Neurovascular Research PET and SPECT Exploration of Central Monoaminergic Transporters for the Development of New Drugs and Treatments in Brain Disorders
Current Pharmaceutical Design The Role of Nuclear Medicine in Vascular Dementia
Vascular Disease Prevention (Discontinued)